PROSTATE CANCER: Radical prostatectomy for early stage prostate cancer

2005 ◽  
Vol 118 (2) ◽  
pp. 16-17
Author(s):  
Dan L. Longo
Oncology ◽  
2021 ◽  
pp. 1-5
Author(s):  
Alessandro Sciarra ◽  
Martina Maggi ◽  
Stefano Salciccia ◽  
Alice Nicolai ◽  
Elisabetta Tortorella ◽  
...  

<b><i>Background:</i></b> Androgen receptor splice variant V7 (AR-V7) was recently detected in circulating tumor cells of castration-resistant prostate cancer (PC) patients and its expression correlated with resistance to new-generation androgen signaling inhibitors. <b><i>Objectives:</i></b> We retrospectively analyzed whether AR-V7 expression was detectable on radical prostatectomy (RP) specimens of untreated nonmetastatic PC cases, and whether it could be associated with progression after surgery. <b><i>Method:</i></b> The expression of AR-V7 and AR-FL (full length) was separately evaluated by immunohistochemistry using a streptavidin-biotin-peroxidase system with 2 anti-AR-V7 and anti-AR-FL rabbit monoclonal antibodies. <b><i>Results:</i></b> 56 PC cases, classified by their clinical risk, were analyzed. Positive expression was found in 24/32 cases in the high-risk group, 4/13 in the intermediate-risk group, and only 2/11 in the low-risk group. We found a significant correlation between AR-V7 positivity and both risk classification (<i>p</i> &#x3c; 0.001) and progression after surgery (<i>p</i> &#x3c; 0.001). <b><i>Conclusions:</i></b> In our population of untreated nonmetastatic PC, AR-V7 is detectable by immunohistochemistry in more than 50% of cases. At this early stage, AR-V7 positivity is associated with risk classification and it can predict progression after surgery.


2006 ◽  
Vol 175 (4S) ◽  
pp. 507-507 ◽  
Author(s):  
Makoto Ohori ◽  
James A. Eastham ◽  
Hideshige Koh ◽  
Kentaro Kuroiwa ◽  
Kevin M. Slawin ◽  
...  

2002 ◽  
Vol 20 (12) ◽  
pp. 2869-2875 ◽  
Author(s):  
Jeffrey H. Burkhardt ◽  
Mark S. Litwin ◽  
Christopher M. Rose ◽  
Roy J. Correa ◽  
Jonathan H. Sunshine ◽  
...  

PURPOSE: Radical prostatectomy and external-beam radiation are the most common treatments for localized prostate cancer. Given the absence of clinical consensus in favor of one treatment or the other, relative costs may be a significant factor. This study compares the direct medical costs during the month before and 9 months after diagnosis for patients treated primarily with external-beam radiation or radical prostatectomy for early-stage prostate cancer. METHODS: Patients age 65 or older and coded by the Surveillance, Epidemiology, and End Results (SEER) registry as having been diagnosed with adenocarcinoma of the prostate treated primarily with external-beam radiation or radical prostatectomy during 1992 and 1993 were identified. The initial treatment costs, as measured by Medicare-approved payment amounts, for each strategy were analyzed using linked SEER-Medicare claims data after adjusting for differences in comorbidity and age. An intent-to-treat analysis was also performed to adjust for differences in staging between the two groups. RESULTS: For patients in the treatment-received analysis, the average costs were significantly different; $14,048 (95% confidence interval [CI], $13,765 to $14,330) for radiation therapy and $17,226 (95% CI, $16,891 to $17,560) for radical prostatectomy (P < .001). The average costs for patients in the intent-to-treat analysis were also significantly less for radiation therapy patients ($14,048; 95% CI, $13,765 to $14,330) than for those who underwent radical prostatectomy ($17,516; 95% CI, $17,195 to $17,837; P < .001). CONCLUSION: For patients with early-stage prostate cancer, average costs during the initial treatment interval were at least 23% greater for radical prostatectomy than for external-beam radiation. Major limitations of the research include not studying costs after the initial treatment interval and questionable current applicability, given changes in management of early prostate cancer.


Sign in / Sign up

Export Citation Format

Share Document